Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study

BACKGROUND: The vascular endothelial growth factor receptor (VEGFR) pathway plays a pivotal role in solid malignancies and is probably involved in chemotherapy resistance. Pazopanib, inhibitor of, among other receptors, VEGFR1–3, has activity as single agent and is attractive to enhance anti-tumour...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamberg, P, Boers-Sonderen, M J, van der Graaf, W T A, de Bruijn, P, Suttle, A B, Eskens, F A L M, Verweij, J, van Herpen, C M L, Sleijfer, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929878/
https://www.ncbi.nlm.nih.gov/pubmed/24366297
http://dx.doi.org/10.1038/bjc.2013.798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929878/
https://www.ncbi.nlm.nih.gov/pubmed/24366297
http://dx.doi.org/10.1038/bjc.2013.798

Ejemplares similares